Heterogeneity in mouse spasmolytic polypeptide-expressing metaplasia lineages identifies markers of metaplastic...

Area of Science:

• Gastroenterology
• Oncology
• Molecular Biology

Background:

• Spasmolytic polypeptide-expressing metaplasia (SPEM) is a preneoplastic lesion in the stomach.
• SPEM arises after parietal cell loss in both mice and humans.
• Understanding SPEM lineage differences is crucial for identifying progression markers.

Purpose of the Study:

• To compare phenotypic SPEM lineages from different mouse models.
• To identify common and distinct molecular markers of SPEM.
• To investigate the role of clusterin and CFTR in SPEM progression.

Main Methods:

• Utilized three mouse models of parietal cell loss with varying inflammation.
• Compared RNA transcripts from normal chief cells and SPEM using gene microarray.
• Validated transcript alterations via quantitative real-time PCR and immunohistochemistry.

Main Results:

• Distinct transcript expression patterns were observed among SPEM models.
• Clusterin was upregulated in all mouse SPEM and human SPEM, correlating with poor survival in gastric cancer.
• CFTR was upregulated in inflamed murine SPEM and in human intestinal metaplasia, but not human SPEM.

Conclusions:

• Clusterin serves as a common marker for all SPEM lineages.
• Distinct gene patterns, like CFTR upregulation, signify progression towards intestinal metaplasia, particularly in inflamed conditions.
• These findings highlight molecular differences in metaplasia development and progression.